These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 21095450

  • 41. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 42. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ, Shankel T, Deming D, Cutler D, Sahney S, Fitts J, Chinnock RE.
    Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
    [Abstract] [Full Text] [Related]

  • 46. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 47. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J, Hunziker T, Martinelli M, Koestner SC, Mohacsi PJ.
    Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q.
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [Abstract] [Full Text] [Related]

  • 51. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
    Chen KH, Lee CY, Wu FL, Yang CY, Yeh CC, Hu RH, Tsai MK.
    J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
    [Abstract] [Full Text] [Related]

  • 52. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO, Müller S, Konstandin M, Celik S, Kristen A, Frankenstein L, Ehlermann P, Sack FU, Katus HA, Dengler TJ.
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009 Nov; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 55. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 56. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 May; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 57. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 58. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
    de Fijter JW.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
    [Abstract] [Full Text] [Related]

  • 59. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 60. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Nov; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.